Welcome to our dedicated page for Mangoceuticals news (Ticker: MGRX), a resource for investors and traders seeking the latest updates and insights on Mangoceuticals stock.
Mangoceuticals, Inc. (NASDAQ: MGRX) is a dynamic company focusing on the development, marketing, and sale of men's wellness products and services. Specializing in telemedicine, Mangoceuticals provides a convenient platform for men to access essential healthcare. Through this platform, customers can connect with licensed pharmacies to obtain medications prescribed during telehealth consultations. One of the flagship offerings includes Mango ED products, which have gained significant attention for their effectiveness and ease of access.
In recent achievements, Mangoceuticals has expanded its portfolio to include a wider range of wellness products, continually enhancing user experience and accessibility. The company’s ongoing projects focus on integrating advanced telemedicine technologies to streamline consultation and prescription processes. Financially, Mangoceuticals has shown promising growth, with strategic partnerships bolstering its market presence and operational capabilities.
Mangoceuticals is committed to providing quality healthcare solutions tailored to men's needs, ensuring privacy, convenience, and professional guidance at every stage. Investors and stakeholders can expect steady updates on the company's performance, new product launches, and strategic developments, making MGRX a noteworthy stock in the wellness and telemedicine sectors.
Mangoceuticals (NASDAQ: MGRX) has announced the launch of PeachesRx, a women's telehealth platform focusing on health and wellness products, initially specializing in GLP-1 receptor agonists for weight loss treatment. The platform will operate through www.PeachesRx.com, offering HIPAA-compliant telemedicine services.
The company is targeting the expanding GLP-1 market, where approximately 70% of weight loss prescriptions are written for women. The global GLP-1 market for weight management is projected to exceed $48 billion by 2030. The women's health market, valued at $49.33 billion in 2024, is expected to reach $68.53 billion by 2030, growing at a 5.1% CAGR.
Studies indicate that over 60% of telehealth users are female, positioning PeachesRx to capture this market segment. The company plans to expand beyond GLP-1 treatments into broader wellness categories, including sexual health, hair growth, and hormone therapy solutions.
Mangoceuticals (NASDAQ: MGRX) is advancing research on respiratory illness prevention technology, focusing on combating avian influenza (H5N1) in the poultry industry. The company has engaged Vipragen Biosciences to conduct efficacy studies for an antiviral solution using their patented technology acquired from IntraMont Technologies.
The company is developing a water-based application for poultry using Generally Recognized as Safe (GRAS) ingredients. Phase I animal studies have shown significant efficacy in reducing lung viral load, and Phase II studies are ongoing. The solution aims to address the devastating impact of avian flu, which has led to the culling of over 148 million birds in the US since 2022 and caused egg prices to reach $4.15 per dozen as of December 2024, with a projected 20% increase in 2025.
The company targets the global poultry market, projected to reach $375.41 billion by 2030, offering a potential non-pharmaceutical preventive solution for the industry.
Mangoceuticals (NASDAQ: MGRX) has announced significant progress in its H1N1 efficacy study, reporting a substantial reduction in viral load during Phase 1 animal trials. The company is now advancing to the next research stage while simultaneously expanding its focus to include H5N1 (Avian Influenza) studies.
The research, conducted by Vipragen Biosciences in India, utilizes Mangoceuticals' proprietary formulation combining advanced polyphenol and zinc chemistry. The H5N1 cohort will run concurrently with the ongoing H1N1 study, demonstrating the company's commitment to addressing multiple respiratory illness threats.
The company plans to disclose final results after completing the studies and securing proper intellectual property protections through provisional filings.
Mangoceuticals (NASDAQ: MGRX) has entered into an exclusive Master Distribution Agreement with Propre Energie for Dermytol®, a clinically proven skincare treatment targeting hyperpigmentation. The agreement grants MGRX exclusive rights to market, sell, and distribute Dermytol® across North and South America.
Dermytol® is an advanced, plant-based formula proven more effective than Kojic acid at reducing melanin production while causing less damage to skin cells. The product utilizes a proprietary blend of ingredients including canola phenolic acid, Camellia sinensis tea extract, evening primrose, and aloe vera.
The partnership targets the growing global skincare market, projected to reach $218 billion by 2029 with a 3.61% CAGR. The plant-based skincare segment specifically is expected to grow from $789.75 million in 2023 to $1.62 billion by 2033, representing a 7.5% CAGR.
Mangoceuticals (NASDAQ: MGRX) has acquired patent WO 2023/086647 PCT/US2022/049857 for mushroom-derived compositions and treatment methods. The patent covers nutraceutical formulations from functional mushrooms including Cordyceps sinensis, Ganoderma lucidum (Reishi), and Hericium erinaceus (Lion's Mane), designed to enhance immune function, cognitive performance, mood, and provide adaptogenic benefits.
The company plans to develop new wellness products leveraging this patent, including dietary supplements and functional foods. The acquisition aligns with the growing functional mushroom market, which is valued at $32.41 billion in 2024 and projected to reach $48.59 billion by 2029, with a CAGR of 8.44% according to Mordor Intelligence.
Mangoceuticals (NASDAQ: MGRX) has initiated an investigation into potential stock manipulation following its October 16, 2024 reverse stock split. The company identified suspicious trading patterns and an unusual surge in shareholder accounts. The Depository Trust Company (DTC) requested 213,327 additional shares for fractional share 'round-up', representing about 9% of MangoRx's 2.4 million post-split outstanding shares.
Prior to the split, MangoRx had approximately 5,000 shareholders, but trading patterns suggest a potential increase of over 200,000 accounts post-split. The company observed numerous high-frequency single-share transactions around the split date. CEO Jacob Cohen has denied DTC's request pending investigation completion. MangoRx notes similar patterns to those reported by Upexi Inc. (NASDAQ:UPXI), which experienced comparable irregularities in their recent reverse stock split.
Mangoceuticals (NASDAQ: MGRX) has regained full compliance with Nasdaq's minimum bid price requirement. The company received confirmation from Nasdaq on October 30, 2024, stating that its common stock maintained a closing bid price at or above $1.00 per share for 10 consecutive business days, meeting the requirements of Nasdaq Listing Rule 5550(a)(2). With this compliance achievement, the listing matter is now closed.
MangoRx (NASDAQ: MGRX), a company specializing in men's health and wellness products via telemedicine, has announced the formation of a Strategy and Alternatives Committee. The company's Board of Directors has initiated a process to evaluate potential strategic alternatives aimed at maximizing shareholder value.
These alternatives may include mergers, acquisitions, divestitures, business combinations, entry into new lines of business, expansions, and joint ventures. This initiative will run parallel to MangoRx's current operations. The company plans to consult with financial and legal advisors to consider a wide range of strategic, operational, and financial options.
MangoRx has not set a timeline for completing this review process and does not intend to provide further comments unless necessary. The company emphasizes that there is no guarantee that this strategic review will result in any specific transaction or outcome.
MangoRx (NASDAQ: MGRX), a company focused on men's health and wellness products, has responded to claims made by Eli Lilly. Eli Lilly has allegedly filed a lawsuit against MangoRx, claiming that the company improperly copied its weight-loss medicines, Zepbound and Mounjaro. MangoRx strongly refutes these claims regarding the sale of compounded tirzepatide and intends to vigorously defend itself.
The company believes it has strong arguments against Eli Lilly's claims and remains committed to providing access to safe and efficacious products prescribed by U.S. licensed practitioners. MangoRx plans to continue enhancing patient care through innovative solutions while striving to comply with regulatory guidelines.
Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, has announced its participation in the Centurion One Capital 2nd Annual Bahamas Summit 2024. The event will take place at the Rosewood Baha Mar Hotel in Nassau, Bahamas, from October 22nd to 23rd, 2024.
Jacob Cohen, Founder and CEO of Mangoceuticals, is scheduled to present on Wednesday, October 23rd at 11:10 EDT. He will also be available to field investor questions during the summit. The event will feature presentations from public and private companies across various industries, providing opportunities to showcase their businesses to prominent investors in the growth space from Canada, the United States, and abroad.
FAQ
What is the current stock price of Mangoceuticals (MGRX)?
What is the market cap of Mangoceuticals (MGRX)?
What is Mangoceuticals, Inc.?
What products does Mangoceuticals offer?
How does Mangoceuticals' telemedicine platform work?
What recent achievements has Mangoceuticals made?
What is the financial condition of Mangoceuticals?
Who can benefit from Mangoceuticals' services?
What is the significance of Mango ED products?
What makes Mangoceuticals noteworthy in the stock market?
How does Mangoceuticals ensure the privacy of its customers?
What should investors expect from Mangoceuticals in the future?
